Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220721

Enrollment

105

Registered

2009-04-20

Start date

2009-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinitis pigmentosa

Interventions

investigational material(s) Generic name etc : UF-021 (isopropyl unoprostone) INN of investigational material : Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Decimal visual acuity: 0.5 or better With abnormal visual field measured by the Goldmann perimetry

Exclusion criteria

Exclusion criteria: The subject has taken steroids and/or vasodilators within 1 month prior to informed consent.

Design outcomes

Primary

Measure	Time frame
Efficacy and safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026